TOPICS

Final pressure from pharmaceutical companies to advertise their drugs

Final pressure from pharmaceutical companies to advertise their drugs


We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

By Miguel Jara

The pharmaceutical industry is pressuring the European authorities to allow laboratories to also advertise prescription drugs, something that today only the United States and New Zealand allow. The change in the norms finalized by the European Commission under the excuse of "patient information", will support the industry to "inform" the consumer directly about prescription drugs, says Jesús Acebillo, president of Farmaindustria and general director of the laboratory Novartis.


The pharmaceutical industry is pressuring the European authorities to allow laboratories to also advertise prescription drugs, something that today only the United States and New Zealand allow. The regulatory change on the rules that prohibit advertising drugs as if they were vulgar objects of consumption, and finalized by the European Commission under the excuse of "patient information", will support the industry to "inform" the consumer directly about prescription drugs, says Jesús Acebillo, president of Farmaindustria and CEO of the Novartis laboratory. At the moment, the draft directive was due to be presented to Parliament in the first days of November but has been delayed, according to sources in Parliament itself, in part due to opposition from many sectors to the industry "reporting" - advertising - directly to the patient.

We have had access to the draft prepared by the Directorate of Business and Industry of the European Commission whose standard, if approved in the coming months, would further increase the cases of iatrogenesis and could definitely lead to the collapse of health systems; especially since the idea is that the advertising focuses on the "new" drugs. I tell it in the number that is in the street of the publication Discovery DSalud - an exclusive one for Spanish speakers - and I tell you some of the ins and outs of the draft Directive that is on the table of the European Commission.

The Death by Medicine study highlights that adverse drug reactions - both outside and inside hospitals - cause 305,000 deaths each year in the United States alone. As we say, this is one of the two countries that allow advertising of prescription drugs. Pharmaceutical laboratories are sponsoring a change in the European regulation of what is called Direct Consumer Advertising (or DTCA for its acronym in English) and for this the modification of Directive 2001l83 / EC - current community code on medicines for human use- and thus achieve the same goal but in a subtle way. "The general policy objectives of the proposal are in line with the general objectives of Community pharmaceutical legislation. These are intended to ensure the proper functioning of the internal market for medicinal products for human use and to better protect the health of the citizens of the European Union ", can be read in the draft that the European Commission handles. This body, the one with the greatest decision-making power in Europe, does not beat around the bush: first the market, then the people.


In addition, the definition of advertising would be eliminated. In no section of the suggested text does it speak of advertising, only of "information". If the draft was approved as is, "information campaigns" in newspapers, magazines, supplements, brochures and the Internet would be allowed. And radio and television are not included because it is understood that the information would not be selective, it would not reach only "to those who wish to receive it" (as if in a newspaper or magazine the advertising was selective and did not reach everyone who acquires a copy ). Regarding the case of the Internet, the draft suggests a certain obsession with the much information that the network offers about medicines, something that, especially critical information, does not like the pharmaceutical companies. It is also stated, in a certainly suspicious way, that it will not be possible to make comparisons of efficacy -or otherwise- between products. In other words, exactly what could be of interest to the consumer would be prohibited if it is done from a critical point of view because in many cases laboratories compare their medicines only with those that are demonstrably worse than theirs and they use it in a promotional. On the other hand, it would be possible to publish information from phase IV studies, that is, when a drug is being tested in a massive way to really verify its side effects.

On the other hand, the current proposal allows the pharmaceutical industry to "regulate itself" through a manual of "good behavior". In other words, the laboratories would first promote their drugs and then, once on the market, they would respond to the courts or before the health authorities if the promotion is unethical or if their consumption causes serious damage to health. When the ex post controls have already proven to be absolutely ineffective. It shows that in the United States the FDA - the agency that regulates drugs - is currently totally overwhelmed by alerts and complaints.

What's more, the reality is that today many laboratories run advertising campaigns with clearly misleading claims -if not overtly false- for months, earn huge amounts and do not stop doing so until a resolution is adopted to ban them, which usually happens when the campaign has now ended. In short, manufacturers avoid any prior control.

It should be remembered that the industry already "self-regulates" today the promotion of drugs among doctors and that does not mean that the "rent" of wills has ended - based on "gifts" or even cash. A shameful and perhaps even profitable practice from an economic point of view but which has begun to take its toll on the pharmaceutical industry from a social point of view because more and more people are understanding their level of ethics. In fact, knowing that their image is deteriorating at times in the proposed new directive there is practically no reference to healthcare professionals as providers of information on health issues other than saying that these measures are not intended to replace them. In other words, the laboratories would not have them as they have been up to now, proof of their clear advertising intention.

In a few days I will offer more details of the draft that the European Commission may approve.

Miguel Jara - Freelance journalist - http://migueljara.wordpress.com/

Other infos: http://migueljara.wordpress.com/2008/11/27/quieren-hacer-pruebas-del-vih-a-los-inmigrantes-en-las-farmacias/
http://migueljara.wordpress.com/2008/11/26/drogas-para-la-infancia-trabas-al-comercio-de-ritalin/


Video: Joe Rogan Reacts to Ridiculous Pharmaceutical Drug Ads (July 2022).


Comments:

  1. Nulte

    You are absolutely right. In it something is and it is excellent idea. It is ready to support you.

  2. Astolpho

    It is with this article that I begin to read this blog. Plus one subscriber :)

  3. Arashizahn

    Well, how could it be? I am looking for how to clarify this topic.

  4. Courtland

    we can say this is an exception :)

  5. Tygosida

    interesting, and the analog is?

  6. Kaden

    I consider, that you are mistaken. Let's discuss. Email me at PM, we will talk.



Write a message